Compare Stocks: THRD, GERN, DSGN, and ANNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.87 +0.6%	$5.38	$2.10 ▼ $7.18	$923.25M	1.21	2.44 million shs	1.23 million shs
DSGN Design Therapeutics	$15.14 +0.7%	$14.12	$5.28 ▼ $17.25	$947.49M	1.66	554,668 shs	256,616 shs
GERN Geron	$1.57 +4.0%	$1.47	$1.04 ▼ $2.01	$1.01B	0.61	9.45 million shs	11.48 million shs
THRD Third Harmonic Bio	$5.38	$0.00	$0.00 ▼ $0.00	$242.80M	2.12	247,013 shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

The AI boom extends far beyond the biggest tech names. Discover 10 companies supplying the memory, storage, networking, semiconductor manufacturing, and power infrastructure that make AI possible. Learn where the next wave of AI investment opportunities may emerge—and the key risks investors should watch as the global AI buildout accelerates.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-2.01%	-13.04%	-7.94%	+137.56%
DSGN Design Therapeutics	0.00%	+0.20%	+9.95%	+42.16%	+154.03%
GERN Geron	0.00%	+3.97%	0.00%	+34.19%	+12.14%
THRD Third Harmonic Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ANNX Annexon	$4.87 +0.6%	$5.38	$2.10 ▼ $7.18	$923.25M	1.21	2.44 million shs	1.23 million shs
DSGN Design Therapeutics	$15.14 +0.7%	$14.12	$5.28 ▼ $17.25	$947.49M	1.66	554,668 shs	256,616 shs
GERN Geron	$1.57 +4.0%	$1.47	$1.04 ▼ $2.01	$1.01B	0.61	9.45 million shs	11.48 million shs
THRD Third Harmonic Bio	$5.38	$0.00	$0.00 ▼ $0.00	$242.80M	2.12	247,013 shs	N/A

The Infrastructure's Backbone: 10 Stocks Powering the AI Buildout

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ANNX Annexon	0.00%	-2.01%	-13.04%	-7.94%	+137.56%
DSGN Design Therapeutics	0.00%	+0.20%	+9.95%	+42.16%	+154.03%
GERN Geron	0.00%	+3.97%	0.00%	+34.19%	+12.14%
THRD Third Harmonic Bio	0.00%	0.00%	0.00%	0.00%	0.00%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ANNX Annexon	2.40	Hold	$15.14	210.94% Upside
DSGN Design Therapeutics	2.88	Moderate Buy	$16.50	8.98% Upside
GERN Geron	2.20	Hold	$4.00	154.78% Upside
THRD Third Harmonic Bio	0.00	N/A	N/A	N/A

Current Analyst Ratings Breakdown

Latest THRD, GERN, DSGN, and ANNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/1/2026	ANNX Annexon	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$10.00 ➝ $14.00
8/13/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Underperform ➝ Market Perform
8/11/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
7/24/2026	GERN Geron	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
7/21/2026	ANNX Annexon	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform
7/21/2026	ANNX Annexon	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Market Underperform	$3.00
7/20/2026	ANNX Annexon	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$14.00
7/17/2026	ANNX Annexon	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	DSGN Design Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/15/2026	ANNX Annexon	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$11.00 ➝ $25.00
7/13/2026	ANNX Annexon	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight

(Data available from 9/6/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ANNX Annexon	N/A	N/A	N/A	N/A	$0.98 per share	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	$3.23 per share	N/A
GERN Geron	$183.88M	5.49	N/A	N/A	$0.34 per share	4.62
THRD Third Harmonic Bio	N/A	N/A	N/A	N/A	$6.33 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ANNX Annexon	-$206.69M	-$1.16	N/A	N/A	N/A	N/A	-106.15%	-79.82%	11/9/2026 (Estimated)
DSGN Design Therapeutics	-$69.79M	-$1.18	N/A	N/A	N/A	N/A	-34.03%	-32.05%	11/4/2026 (Estimated)
GERN Geron	-$83.50M	-$0.11	N/A	26.17	N/A	-34.17%	-24.48%	-10.30%	11/4/2026 (Estimated)
THRD Third Harmonic Bio	-$45.47M	-$0.62	N/A	N/A	N/A	N/A	-19.27%	-18.67%	N/A

Latest THRD, GERN, DSGN, and ANNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/12/2026	Q2 2026	ANNX Annexon	-$0.2388	-$0.28	-$0.0412	-$0.28	$6.50 million	N/A
8/5/2026	Q2 2026	GERN Geron	-$0.0089	-$0.02	-$0.0111	-$0.02	$55.30 million	$57.48 million
8/3/2026	Q2 2026	DSGN Design Therapeutics	-$0.3443	-$0.32	+$0.0243	-$0.32	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ANNX Annexon	N/A	N/A	N/A	N/A	N/A
DSGN Design Therapeutics	N/A	N/A	N/A	N/A	N/A
GERN Geron	N/A	N/A	N/A	N/A	N/A
THRD Third Harmonic Bio	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ANNX Annexon	N/A	5.53	5.53
DSGN Design Therapeutics	N/A	18.86	18.86
GERN Geron	0.55	6.91	5.16
THRD Third Harmonic Bio	N/A	54.10	54.10

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ANNX Annexon	N/A
DSGN Design Therapeutics	56.64%
GERN Geron	73.71%
THRD Third Harmonic Bio	93.95%

Insider Ownership

Company	Insider Ownership
ANNX Annexon	10.31%
DSGN Design Therapeutics	17.10%
GERN Geron	1.71%
THRD Third Harmonic Bio	7.80%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ANNX Annexon	60	189.58 million	170.03 million	Optionable
DSGN Design Therapeutics	40	62.58 million	51.88 million	Optionable
GERN Geron	70	642.47 million	631.49 million	Optionable
THRD Third Harmonic Bio	N/A	45.13 million	41.61 million	No Data

THRD, GERN, DSGN, and ANNX Headlines

Recent News About These Companies

THRD Share News Today

June 25, 2026 | uk.investing.com

Third Harmonic Bio to Delist from Nasdaq

July 31, 2025 | tipranks.com

Third Harmonic Bio, Inc. (THRD) Cash Flow - Yahoo Finance

July 11, 2025 | finance.yahoo.com

Third Harmonic Bio Stock (NASDAQ:THRD), Insider Trading Activity

July 11, 2025 | benzinga.com

Third Harmonic Bio Inc News (THRD) - Investing.com

July 3, 2025 | investing.com

Third Harmonic Bio Announces Stockholder Approval of Plan of Liquidation and Dissolution, Updated THB335 Phase 1 Clinical Data, and Initiation of Sale of THB335

June 12, 2025 | globenewswire.com

Northeast Dominates 2025 Highest Income Rankings, Study Says: See Where Your State Stands

June 9, 2025 | msn.com

Third Harmonic Bio plans to liquidate the company, sell urticaria treatment

April 14, 2025 | msn.com

Third Harmonic Bio Announces Liquidation Plan: Stock Skyrockets 39% Pre-Market, But Retail’s Shattered

April 14, 2025 | msn.com

Third Harmonic Bio Announces Plan of Liquidation and Dissolution

April 14, 2025 | globenewswire.com

Third Harmonic Bio Announces Fourth Quarter and Full Year 2024 Financial Results

March 27, 2025 | globenewswire.com

Third Harmonic Bio, Inc. (THRD) Loses -31.61% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

March 4, 2025 | zacks.com

Third Harmonic Bio, Inc. (THRD) Upgraded to Buy: What Does It Mean for the Stock?

February 14, 2025 | zacks.com

Down -39.61% in 4 Weeks, Here's Why You Should You Buy the Dip in Third Harmonic Bio, Inc. (THRD)

February 14, 2025 | zacks.com

Third Harmonic Bio Announces Phase 1 Clinical Results for THB335 and Provides Corporate Strategic Update

February 11, 2025 | globenewswire.com

Third Harmonic Bio to Participate in the 7th Annual Evercore HealthCONx Conference

November 25, 2024 | globenewswire.com

Apple making foray into smart home IP camera market, says analyst Ming-Chi Kuo

November 13, 2024 | finance.yahoo.com

Updates to the British Virgin Islands Anti-Money Laundering regime and changes for MLROs

November 12, 2024 | jdsupra.com

Wall Street Analysts Believe Third Harmonic Bio, Inc. (THRD) Could Rally 26.67%: Here's is How to Trade

November 11, 2024 | zacks.com

(LEAD) Netmarble swings to black in Q3 on steady-selling titles

November 8, 2024 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRD, GERN, DSGN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

$4.87 +0.03 (+0.62%)

As of 09/4/2026 04:00 PM Eastern

Annexon, Inc., a clinical-stage biopharmaceutical company, discovers and develops medicines for treating inflammatory-related diseases. Its lead candidate is ANX005, an investigational full-length monoclonal antibody, which is in Phase 3 clinical trial for the treatment of patients with guillain-barré syndrome; completed Phase II clinical trial for treating Huntington's disease; and in Phase II clinical trial for the treatment of amyotrophic lateral sclerosis. The company is also developing ANX007, an antigen-binding fragment (Fab) that is in Phase 3 program for the treatment of patients with geographic atrophy; and ANX1502, a novel oral small molecule inhibitor, which is in Phase 1 clinical trials for autoimmune indications. In addition, it develops ANX009, a C1q-blocking Fab that is in Phase I clinical trial for treating patients with lupus nephritis. The company was incorporated in 2011 and is headquartered in Brisbane, California.

Design Therapeutics NASDAQ:DSGN

$15.14 +0.11 (+0.73%)

As of 09/4/2026 04:00 PM Eastern

Design Therapeutics, Inc. a biopharmaceutical company, researches, designs, develops, and commercializes small molecule therapeutic drugs for the treatment of genetic diseases in the United States. The company utilizes its GeneTAC platform to design and develop therapeutic candidates for inherited diseases caused by nucleotide repeat expansion. Its lead product candidates for potentially disease-modifying treatment comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function that brings to neurological, cardiac, and metabolic dysfunction; Myotonic Dystrophy Type-1, a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs; Fuchs Endothelial Corneal Dystrophy, a genetic eye disease characterized by bilateral degeneration of corneal endothelial cells and progressive loss of vision; and Huntington's Disease, a dominantly inherited, monogenic neurodegenerative disease characterized by movement, cognitive, and psychiatric disorders. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.

Geron NASDAQ:GERN

$1.57 +0.06 (+3.97%)

As of 09/4/2026 04:00 PM Eastern

Geron Corporation, a late-stage clinical biopharmaceutical company, focuses on the development and commercialization of therapeutics for myeloid hematologic malignancies. It develops imetelstat, a telomerase inhibitor that is in Phase 3 clinical trials, which inhibits the uncontrolled proliferation of malignant stem and progenitor cells in myeloid hematologic malignancies for the treatment of low or intermediate-1 risk myelodysplastic syndromes and intermediate-2 or high-risk myelofibrosis. The company was incorporated in 1990 and is headquartered in Foster City, California.

Third Harmonic Bio NASDAQ:THRD

TF Financial Corporation is a savings and loan holding company. The Company's direct and indirect subsidiaries include Third Federal Bank (the Bank), Teragon Financial Corporation, Penns Trail Development Corporation and Third Delaware Corporation. The Bank is a community oriented Pennsylvania stock savings bank offering a variety of financial services to meet the needs of the communities it serves. As of December 31, 2011 the Bank operated fourteen branch offices in Bucks and Philadelphia Counties, Pennsylvania and in Mercer County, New Jersey. During the year ended December 31, 2011, the Company's subsidiary, TF Investments Corporation merged into TF Financial Corporation. In July 2013, the Company acquired Roebling Financial Corp, Inc. (Roebling) and its wholly-owned subsidiary, Roebling Bank.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THRD, GERN, DSGN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THRD, GERN, DSGN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THRD, GERN, DSGN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRD, GERN, DSGN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

Third Harmonic Bio NASDAQ:THRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest THRD, GERN, DSGN, and ANNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest THRD, GERN, DSGN, and ANNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

THRD, GERN, DSGN, and ANNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

THRD, GERN, DSGN, and ANNX Company Descriptions

Annexon NASDAQ:ANNX

Design Therapeutics NASDAQ:DSGN

Geron NASDAQ:GERN

Third Harmonic Bio NASDAQ:THRD

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools